Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-? in oral cancer patients

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

1987 • 2,769 citations

A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes

1986 • 1,787 citations

Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

1987 • 1,224 citations

The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes.

1986 • 1,106 citations

Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity

1981 • 703 citations

Augmentation of natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic target cells

1977 • 288 citations

Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).

1985 • 184 citations

An Acquired Chemotactic Defect in Neutrophils from Patients Receiving Interleukin-2 Immunotherapy

1990 • 149 citations

Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells

1984 • 116 citations

Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.

1988 • 80 citations

Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment.

1990 • 75 citations

Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.

1989 • 70 citations

Activation of protein kinase C in neutrophil cytoplasts

1985 • 68 citations

Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.

1989 • 62 citations

Characterization and modulation of human lymphokine (interleukin 2) activated killer cell induction.

1986 • 59 citations

Human Cytotoxic T Cells Specific for Autologous Melanoma Cells: Successful Generation From Lymph Node Cells in Seven Consecutive Cases

1988 • 56 citations

Role of intracellular calcium concentration and protein kinase C activation in IFN-gamma stimulation of U937 cells.

1990 • 51 citations

Up‐ and down‐regulation of human lymphokine (IL‐2)‐activated killer cell induction by monocytes, depending on their functional state

1988 • 49 citations

Prerequisite for the induction of lymphokine-activated killer cells from T lymphocytes.

1988 • 45 citations

CD8⁺CD11b⁺ peripheral blood T lymphocytes contain lymphokine‐activated killer cell precursors

1989 • 43 citations

Endogenous inhibitor of protein kinase C: association with human peripheral blood neutrophils but not with specific granule-deficient neutrophils or cytoplasts.

1986 • 38 citations

Autologous lymph node cell-derived tumor-specific cytotoxic t-cells for use in adoptive immunotherapy of human melanoma

1988 • 36 citations

the influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2

1990 • 31 citations

Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.

1989 • 30 citations

Expression of class II antigens by subsets of activated T cells

1986 • 17 citations

Three Schedules of Recombinant Human Interleukin‐2 in the Treatment of Malignancy: Side Effects and Immunologic Effects in Relation to Serum Level

1988 • 16 citations

Compared mechanisms of tumor cytolysis by human natural killer cells and activated polymorphonuclear leukocytes.

1984 • 16 citations

A phase I study of an outpatient regimen of recombinant human interleukin-2 and alpha-2a-interferon in patients with solid tumors

1991 • 15 citations

Interleukin-2-dependent long-term cultures of low-density lymphocytes allow the proliferation of lymphokine-activated killer cells with natural killer, Tiγ/δ or TNK phenotype

1990 • 10 citations

Cited By (0)

Loading...